PAP
EW icon

Persistent Asset Partners’s Edwards Lifesciences EW Stock Holding History

Persistent Asset Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$438K Sell
4,846
-2,069
-30% -$173K 0.13% 127
2026
Q1 		$554K Buy
6,915
+1,154
+20% +$95.1K 0.21% 104
2025
Q4 		$491K Buy
+5,761
New +$473K 0.22% 130

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Persistent Asset Partners's EW Position: Q2 2026 in Review

Persistent Asset Partners reduced its Edwards Lifesciences (EW) stake by 30% in Q2 2026, selling an estimated $173K and leaving 4,846 shares worth $438K. The position accounts for 0.13% of the portfolio, ranked #127.

Persistent Asset Partners first reported a position in EW in Q4 2025 and has held it in 3 quarters since. The position peaked at $554K in Q1 2026. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Persistent Asset Partners held 4,846 shares of Edwards Lifesciences worth $438K as of Q2 2026.
  • Persistent Asset Partners sold 2,069 Edwards Lifesciences shares in Q2 2026, an estimated $173K.
  • Edwards Lifesciences made up 0.13% of Persistent Asset Partners's portfolio in Q2 2026, its #127 holding.
  • Persistent Asset Partners first reported a position in Edwards Lifesciences in Q4 2025 and has held it in 3 quarters since.
  • Persistent Asset Partners's Edwards Lifesciences position peaked at $554K in Q1 2026.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.